ArticleMarine drugs2017
Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria sp. NH-F6.
Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Two Decades of Research on Marine-DerivedMarine drugs · 2025Review
- Natural resorcylic lactones derived from alternariol.Beilstein journal of organic chemistry · 2024Review
- Metabolomic Strategy to Characterize the Profile of Secondary Metabolites inMolecules (Basel, Switzerland) · 2022Article
- Cytotoxic Potential ofCurrent issues in molecular biology · 2022Article
- Secondary metabolites ofFrontiers in microbiology · 2022Review
- Metabolites of Marine Sediment-Derived Fungi: Actual Trends of Biological Activity Studies.Marine drugs · 2021Review
- Review
- Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception.Journal of cancer prevention · 2020Review
- Article
- Glycosylated Natural Products From Marine Microbes.Frontiers in chemistry · 2019Review
- Novel Natural Products from Extremophilic Fungi.Marine drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromodomains (BRD) are readers of the epigenetic code that regulate gene transcription through their recognition of acetyl-lysine modified histone tails. Recently, bromodomain-containing proteins such as BRD4 have been demonstrated to be druggable through the discovery of potent inhibitors. These protein-protein interaction inhibitors have the potential to modulate multiple diseases by their profound anti-inflammatory and antiproliferative effects. In order to explore new BRD4 inhibitors as well as lead compounds for the development of new drugs, the secondary metabolites of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.